REFERENCES
- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277 - 300; http://dx.doi.org/10.3322/caac.20073; PMID: 20610543
- Vergati M, Intrivici C, Huen NY, Schlom J, Tsang KY. Strategies for cancer vaccine development. J Biomed Biotechnol 2010; 2010:596432; http://dx.doi.org/10.1155/2010/596432; PMID: 20706612
- Aldrich JF, Lowe DB, Shearer MH, Winn RE, Jumper CA, Kennedy RC. Vaccines and immunotherapeutics for the treatment of malignant disease. . Clin Dev Immunol 2010; 2010:697158; http://dx.doi.org/10.1155/2010/697158; PMID: 20936120
- Andersen MH, Junker N, Ellebaek E, Svane IM, Thor Straten P. Therapeutic cancer vaccines in combination with conventional therapies. J Biomed Biotechnol 2010; 2010:237623; http://dx.doi.org/10.1155/2010/237623; PMID: 20617155
- Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al, IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411 - 22; http://dx.doi.org/10.1056/NEJMoa1001294; PMID: 20818862
- Brower V. Approval of Provenge seen as first step for cancer treatment vaccines. J Natl Cancer Inst 2010; 102:1108 - 10; http://dx.doi.org/10.1093/jnci/djq295; PMID: 20668267
- Davis MM, Dayoub EJ. A strategic approach to therapeutic cancer vaccines in the 21st century. JAMA 2011; 305:2343 - 4; http://dx.doi.org/10.1001/jama.2011.814; PMID: 21642687
- National Cancer Institute clinical trials database. http://www.cancer.gov/clinicaltrials/search. Accessed February 27, 2011.
- National Cancer Institute. Cancer vaccine fact sheet. http://www.cancer.gov/cancertopics/factsheet/Therapy/cancer-vaccines. Accessed February 27, 2011.
- U.S. National Institutes of Health. ClinicalTrials.gov. http://www.clinicaltrials.gov. Accessed February 27, 2011.
- Davis MM, Butchart AT, Coleman MS, Singer DC, Wheeler JRC, Pok A, et al. The expanding vaccine development pipeline, 1995-2008. Vaccine 2010; 28:1353 - 6; http://dx.doi.org/10.1016/j.vaccine.2009.11.007; PMID: 19932670